(News Bulletin 247) – Theraclion announced Thursday the success of its capital increase of 8.4 million euros intended to ensure its financial visibility for the next two years.
The company, at the origin of a robotic platform for non-invasive echotherapy, indicates that it has issued 14.5 million new shares accompanied by share subscription warrants (ABSA), a nominal unit value of 0.577 euro.
Theraclion specifies that the Chinese pharmaceutical group Furui subscribed 10.4 million ABSA through its French subsidiary, representing a subscription of six million euros.
In total, Furui invested seven million euros, taking into account the one million euros per exercise of stock warrants conditional on the achievement of milestones.
As part of their strategic partnership, Theraclion and Furui have planned to collaborate to establish a production capacity in China around Sonovein (for varicose veins) and Echopulse (for breast fibroadenomas and thyroid nodules).
The licensing of its technologies and the authorization to use its brands in China will trigger a payment of three million euros linked to the achievement of specific objectives.
Overall, the capital increase, the full exercise of the BSAs and the payment of license fees constitute overall financing of 12.7 million euros, of which 8.4 million acquired today.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
